Investigating how a specific amino acid affects heart disease risk in people with type 2 diabetes
Official title: The role of alpha-aminoadipic acid (2-AAA) in residual CVD risk in T2D
Funded at Vanderbilt University Medical Center · NIH-10888269 · Data updated 2026-11-12
This study is looking at how a substance called alpha-aminoadipic acid (2-AAA) affects heart disease risk in people with type 2 diabetes, by checking blood samples from a past trial to see how different treatments for blood sugar and cholesterol might change its levels.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project start | July 15, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $131,250 |
| NIH project number | 5R21HL169186-02 |
| Project ID | NIH-10888269 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with type 2 diabetes who are at risk for cardiovascular disease.
✕Less likely to help
Patients without type 2 diabetes or those not at risk for cardiovascular disease may not benefit from this research.
What this research studies
This research focuses on understanding the role of alpha-aminoadipic acid (2-AAA) in cardiovascular disease (CVD) risk among individuals with type 2 diabetes (T2D). The study will analyze existing plasma samples from participants in a previous trial to see how 2-AAA levels are influenced by different treatments aimed at lowering blood sugar and cholesterol. By identifying how this metabolite contributes to CVD risk, the research aims to uncover new pathways for reducing heart disease in T2D patients.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for reducing cardiovascular disease risk in patients with type 2 diabetes.
How similar studies have gone: Previous research has indicated that targeting specific metabolites can influence cardiovascular risk, suggesting potential for success in this novel approach.
Where this research is happening
-
Vanderbilt University Medical Center
Nashville, United States Active
Researchers
- Principal investigator: Ferguson, Jane F — Vanderbilt University Medical Center
- Study coordinator: Ferguson, Jane F
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.